Zobrazeno 1 - 10
of 56
pro vyhledávání: '"A W Broekmans"'
Autor:
Renske M.T. ten Ham, Jarno Hoekman, Anke M. Hövels, Andre W. Broekmans, Hubert G.M. Leufkens, Olaf H. Klungel
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 11, Iss , Pp 121-130 (2018)
Advanced therapy medicinal products (ATMPs) hold promise as treatments for previously untreatable and high-burden diseases. Expectations are high and active company pipelines are observed, yet only 10 market authorizations were approved in Europe. Ou
Externí odkaz:
https://doaj.org/article/d1e10b2078114479a61d2de16d64634b
Autor:
Nicola Bedlington, Hans-Georg Eichler, André W. Broekmans, Richard J. Barker, Solange Corriol-Rohou, Alicia Granados, Ad Schuurman, Jacoline C. Bouvy, Yann Le Cam, Anna Bucsics, Francesca Cerreta
Publikováno v:
Nature Reviews Drug Discovery
'Adaptive' approaches to bringing drugs to market have been widely discussed in recent years. Here, we describe the evolution of the adaptive approach and of concepts developed by ADAPT SMART, a multi-stakeholder consortium funded by the European Inn
Autor:
J.E.F. Zwart van Rijkom, I. Plug, Frits R. Rosendaal, Andre W. Broekmans, Hubert G. M. Leufkens
Publikováno v:
British Journal of Haematology. 119:332-341
In comparison with other biotechnology substitutions, the adoption of recombinant Factor VIII (rFVIII) has been relatively slow. We sent a postal questionnaire to all Dutch haemophilia patients and haemophilia-treating physicians, to determine which
Autor:
André J.A. Elferink, André W. Broekmans, Barbara J. van Zwieten, Roel van Strik, Witte J G Hoogendijk, Jitschak G. Storosum
Publikováno v:
Schizophrenia Bulletin, 28, 193-201. Oxford University Press
Schizophrenia bulletin, 28(2), 193-201. Oxford University Press
Schizophrenia bulletin, 28(2), 193-201. Oxford University Press
In this article we report on a meta-analysis of the published studies of amisulpride conducted in order to demonstrate efficacy on primary negative symptoms in schizophrenia. Four placebo-controlled studies were conducted in patients with predominant
Autor:
André W, Broekmans, Peter G M, Mol
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 158
Recent European legislation has provided new tools to enhance the overseeing of medicinal products in the postmarketing phase. Package leaflets of newly approved medicines contain a black inverted triangle as a signal for enhanced monitoring. The lea
Autor:
Berthold P. R. Gersons, Wim van den Brink, Jitschak G. Storosum, André W. Broekmans, Barbara J. van Zwieten, Roel van Strik, André J.A. Elferink
Publikováno v:
European neuropsychopharmacology, 11(2), 173-180. Elsevier
The original data from the placebo-arms and the tricyclic-arms of all parallel randomized controlled three-arm studies, which had been conducted in the period 1979–1991 for a drug under development in order to obtain marketing authorization for the
Autor:
Hubert G. M. Leufkens, Jeannette van Rijkom, Daan J.A. Crommelin, Andre W. Broekmans, Frans F. H. Rutten
Publikováno v:
Health Policy. 47:255-274
Biotechnology is increasingly regarded as an important reservoir for the development of new and innovative, but generally expensive, pharmaceuticals. At the same time, concerns about cost containment have triggered a keen interest in evaluating and c
Autor:
Wim van den Brink, Barbara J. van Zwieten, Jitschak G. Storosum, Berthold P. R. Gersons, André W. Broekmans
Publikováno v:
American journal of psychiatry, 158(8), 1271-1275. American Psychiatric Association
The purpose of this study was to determine if fear of an increased risk of attempted suicide in placebo groups participating in placebo-controlled studies is an argument against the performance of placebo-controlled trials in studies of major depress
Autor:
Frans F. H. Rutten, Jan J. V. Busschbach, Andre W. Broekmans, Jeannette E. F. Zwart-van Rijkom, Hubertus G. M. Leufkens
Publikováno v:
PharmacoEconomics. 18(2)
To investigate differences in attitudes, knowledge and actual use of economic evaluations in different groups of decision-makers, and to compare the results from the Netherlands with the overall European results of the European Network on Methodology
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 144(16)
The clinical criteria for admission of new drugs to the European common market have become more stringent in recent years. Increasingly often, the manufacturer is required to demonstrate that the new drug offers a clinically visible and relevant bene